MannKind, a biotech company with a $1.3 billion market cap, received two new FDA approvals that could significantly accelerate growth for its existing products. The company has three revenue streams supporting modest growth and sufficient liquidity to fund operations and product launches for about 2.3 years. Despite the positive outlook and a "Strong Buy" rating based on these approvals, MannKind faces execution risks. The approvals mark an important inflection point for the company as it moves through 2026 with multiple catalysts.
Filament Health has shipped its patented psilocybin drug candidate PEX010 to Austin Health in Melbourne for the PSI-PHY trial, the first study to combine psilocybin-assisted physiotherapy for refractory motor functional neurological disorder (FND). S...
The JPMorgan Equity Premium Income ETF (JEPI) delivers attractive monthly income by selling call options, which caps its upside potential. In contrast, three Dividend Kings—Coca-Cola, Johnson & Johnson, and Procter & Gamble—offer lower initial yields...
Netflix's $326 billion streaming business is deeply integrated, making a breakup difficult. Its financials do not separate profits by segments like ads, games, or live events, and global content and technology costs are shared. Splitting the studio f...
Marvell's stock erased most gains following Nvidia CEO Jensen Huang's positive remarks about the company. Finbold's AI analysis predicts a mixed outlook for Marvell, with price targets ranging from a 7.74% drop to a 5.48% rise by September 30, 2026. ...
Tenet Fintech Group announced it will sponsor the Ignite 2026 conference in Montreal, Canada's largest event for bookkeepers and accountants. At the event, Tenet will showcase BKeeper, a new AI-driven platform designed to help bookkeepers connect the...
